CA2265661A1 - Formulation a liberation lente de monohydrochlorure d'acetonitrile r-(z)-alpha-methoxyimino-alpha-(1-azabicyclo2.2.2oct-c-yl) - Google Patents

Formulation a liberation lente de monohydrochlorure d'acetonitrile r-(z)-alpha-methoxyimino-alpha-(1-azabicyclo2.2.2oct-c-yl) Download PDF

Info

Publication number
CA2265661A1
CA2265661A1 CA002265661A CA2265661A CA2265661A1 CA 2265661 A1 CA2265661 A1 CA 2265661A1 CA 002265661 A CA002265661 A CA 002265661A CA 2265661 A CA2265661 A CA 2265661A CA 2265661 A1 CA2265661 A1 CA 2265661A1
Authority
CA
Canada
Prior art keywords
dosage form
coated
beads
form according
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002265661A
Other languages
English (en)
Inventor
Joseph Sauer
Laurence Rousseau
James Albert Napper
William Muldoon
Susan Marie Milosovich
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
SmithKline Beecham Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2265661A1 publication Critical patent/CA2265661A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

Cette invention se rapporte à une formulation à libération lente contenant un composé d'acétonitrile et à son utilisation pour le traitement et/ou la prophylaxie de certains troubles.
CA002265661A 1996-09-12 1997-09-08 Formulation a liberation lente de monohydrochlorure d'acetonitrile r-(z)-alpha-methoxyimino-alpha-(1-azabicyclo2.2.2oct-c-yl) Abandoned CA2265661A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9619074.9A GB9619074D0 (en) 1996-09-12 1996-09-12 Composition
GB9619074.9 1996-09-12
PCT/GB1997/002418 WO1998010762A2 (fr) 1996-09-12 1997-09-08 Formulation a liberation lente de monohydrochlorure de [r-(z)]-alpha-(methoxyimino)-alpha-(1-azabicyclo[2.2.2]oct-3-yl)acetonitrile

Publications (1)

Publication Number Publication Date
CA2265661A1 true CA2265661A1 (fr) 1998-03-19

Family

ID=10799833

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002265661A Abandoned CA2265661A1 (fr) 1996-09-12 1997-09-08 Formulation a liberation lente de monohydrochlorure d'acetonitrile r-(z)-alpha-methoxyimino-alpha-(1-azabicyclo2.2.2oct-c-yl)

Country Status (22)

Country Link
EP (1) EP0929301A2 (fr)
JP (1) JP2001500150A (fr)
KR (1) KR20000036039A (fr)
CN (2) CN1235544A (fr)
AR (1) AR008176A1 (fr)
AU (1) AU724086B2 (fr)
BR (1) BR9711734A (fr)
CA (1) CA2265661A1 (fr)
CO (1) CO5031291A1 (fr)
CZ (1) CZ83299A3 (fr)
GB (1) GB9619074D0 (fr)
HU (1) HUP9904401A3 (fr)
ID (1) ID19589A (fr)
IL (1) IL128781A0 (fr)
MA (1) MA24359A1 (fr)
NO (1) NO991194D0 (fr)
NZ (1) NZ334268A (fr)
PE (1) PE2499A1 (fr)
PL (1) PL332074A1 (fr)
TR (1) TR199900505T2 (fr)
WO (1) WO1998010762A2 (fr)
ZA (1) ZA978133B (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2775597B1 (fr) * 1998-03-04 2001-04-20 Gattefosse Ets Sa Pellet administrable par voie orale apte a ameliorer la biodisponibilite de la substance active, procede de fabrication
PL342600A1 (en) 1998-03-11 2001-06-18 Smithkline Beecham Plc Composition
DE19918325A1 (de) * 1999-04-22 2000-10-26 Euro Celtique Sa Verfahren zur Herstellung von Arzneiformen mit regulierter Wirkstofffreisetzung mittels Extrusion
FR2796840B1 (fr) * 1999-07-26 2003-06-20 Ethypharm Lab Prod Ethiques Comprimes faiblement doses et procede de preparation
US6733781B2 (en) * 2000-12-06 2004-05-11 Wyeth Fast dissolving tablet
AR040682A1 (es) 2002-07-25 2005-04-13 Pharmacia Corp Forma de dosificacion una vez al dia de pramipexol
JP4808612B2 (ja) * 2003-04-25 2011-11-02 田辺三菱製薬株式会社 アルキレンジオキシベンゼン誘導体を含む経口投与用組成物
ATE339192T1 (de) * 2003-05-14 2006-10-15 Eurand Pharmaceuticals Ltd Kontrollierte medikamentfreigabe zusammensetzung mit in vivo mechanikstresswiderstand
US20050142191A1 (en) * 2003-06-23 2005-06-30 Neurochem (International) Limited Pharmaceutical formulations of amyloid inhibiting compounds
JP2005272347A (ja) * 2004-03-24 2005-10-06 Ohara Yakuhin Kogyo Kk 固形製剤の製造方法
KR101406767B1 (ko) 2004-08-13 2014-06-20 베링거 인겔하임 인터내셔날 게엠베하 프라미펙솔 또는 약제학적으로 허용되는 이의 염을함유하는 연장 방출성 정제 제형, 이의 제조방법 및 이의용도
EP2431027A1 (fr) * 2004-08-13 2012-03-21 Boehringer Ingelheim International GmbH Formulation de pastille à libération prolongée contenant du pramipexole ou l'un de ses sels pharmaceutiquement acceptable, son procédé de fabrication et utilisation associée
EP1970056A1 (fr) * 2007-03-15 2008-09-17 Polichem S.A. Formules de dosages à libération retardée/pulsatile spécifique au temps
US9132096B1 (en) 2014-09-12 2015-09-15 Alkermes Pharma Ireland Limited Abuse resistant pharmaceutical compositions

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0392803T3 (da) * 1989-04-13 2004-10-18 Beecham Group Plc Hidtil ukendte forbindelser
GB9409718D0 (en) * 1994-05-14 1994-07-06 Smithkline Beecham Plc Novel compounds
GB9421472D0 (en) * 1994-10-25 1994-12-07 Smithkline Beecham Plc Novel methods
AR004178A1 (es) * 1995-07-29 1998-11-04 Smithkline Beecham Plc Procedimiento para la formulacion de un farmaco, una composicion farmaceutica obtenible mediante este procedimiento y el uso de la misma.

Also Published As

Publication number Publication date
CN1235544A (zh) 1999-11-17
HUP9904401A3 (en) 2001-03-28
WO1998010762A2 (fr) 1998-03-19
CO5031291A1 (es) 2001-04-27
EP0929301A2 (fr) 1999-07-21
ID19589A (id) 1998-07-23
NO991194L (no) 1999-03-11
PL332074A1 (en) 1999-08-30
NO991194D0 (no) 1999-03-11
AR008176A1 (es) 1999-12-09
ZA978133B (en) 1999-04-12
KR20000036039A (ko) 2000-06-26
HUP9904401A2 (hu) 2000-06-28
IL128781A0 (en) 2000-01-31
AU4128897A (en) 1998-04-02
CN1446535A (zh) 2003-10-08
NZ334268A (en) 2000-10-27
AU724086B2 (en) 2000-09-14
TR199900505T2 (fr) 1999-06-21
CZ83299A3 (cs) 1999-08-11
GB9619074D0 (en) 1996-10-23
JP2001500150A (ja) 2001-01-09
PE2499A1 (es) 1999-03-24
BR9711734A (pt) 1999-08-24
WO1998010762A3 (fr) 1998-06-04
MA24359A1 (fr) 1998-07-01

Similar Documents

Publication Publication Date Title
US6468560B2 (en) Controlled release dosage form of [R-(Z)]-α-(methoxyimino)-α-(1-azabicyclo[2.2.2]oct-3yl) acetonitrile monohydrochloride
US6436438B1 (en) Tramadol multiple unit formulations
US8747898B2 (en) Controlled release oral dosage form
CA1264296A (fr) Formules a trois niveaux distincts de liberation
US4794001A (en) Formulations providing three distinct releases
JP2637981B2 (ja) 吸収制御薬剤組成物
US6077533A (en) Powder-layered oral dosage forms
US4904476A (en) Formulations providing three distinct releases
CA2348090C (fr) Systeme d'administration de medicaments par doses pulsees par voie orale
US5807579A (en) Pseudoephedrine combination pharmaceutical compositions
JP3015105B2 (ja) 粉末被覆経口投与剤形
EP0605174B1 (fr) Préparation pharmaceutique à libération retardée et continue
US6589553B2 (en) Controlled release oral dosage form
US20080044467A1 (en) Formulation and process for drug loaded cores
CA2520321A1 (fr) Tablettes comprimees orales de formulations multiparticulaires a liberation prolongee
US20020156133A1 (en) Oral administration forms for administering a fixed tramadol and diclofenac combination
KR20090091084A (ko) 방출성이 제어된 약제학적 제제
US20030224045A1 (en) Combination immediate release sustained release levodopa/carbidopa dosage forms
CA2265661A1 (fr) Formulation a liberation lente de monohydrochlorure d'acetonitrile r-(z)-alpha-methoxyimino-alpha-(1-azabicyclo2.2.2oct-c-yl)
US7060293B1 (en) Powder-layered oral dosage forms
JP2892858B2 (ja) 放出制御製剤およびその製造法
WO2009024858A1 (fr) Forme posologique à libération contrôlée de galantamine
KR100505899B1 (ko) 로라타딘과 슈도에페드린을 함유한 캅셀제 조성물
US8173164B2 (en) Oral administration forms for administering a fixed tramadol and diclofenac combination
CZ146494A3 (en) Ipsapirone healing preparation

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued